Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012 Mar;2(1):21-8. doi: 10.1007/s12348-011-0047-5
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Rothman KJ. Computation of exact confidence intervals for the odds ratio. Int J Biomed Comput. 1975 Jan;6(1):33-9.
Rothman KJ. Computer analysis for case-control studies with individual matching. Int J Biomed Comput. 1974 Oct;5(4):241-7.